Previously, addition of isatuximab (Isa) to standard-of-care lenalidomide-bortezomib-dexamethasone (RVd) in transplant-eligible patients with newly diagnosed multiple myeloma in the GMMG-HD7 trial (ClinicalTrials.gov identifier: NCT03617731) resulted in a …
The OncoAlert Newsletter is now out for June 23-29, 2023
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive nonâsmall cell lung cancer after a previous ROS1 TKI.
Zongertinib demonstrated clinically meaningful efficacy in previously treated HER2-mutated nonâsmall cell lung cancer.
ASTRO welcomes nominations for participation in upcoming practice guidelines. Please complete this form for consideration.
Phase 1 data may support further development of ZN-1041 combination therapies for a larger breast cancer population.
Panelists discuss how the major unmet needs in treating synovial sarcoma include developing targeted therapies that effectively address the SS18::SSX fusion oncogene, improving early detection…
Click on the article title to read more.
